In a clinical comparative cross-over study of 12 chronically hemodialyzed patients, the polycarbonate hemodialyzer membrane disclosed the following features: (1) A drop in neutrophil count to 45 ± 11 % of predialysis values occurred 15 min after the start of dialysis. (2) Plasmatic C3d increased at the initiation of dialysis simultaneously with the nadir of neutropenia but also towards the end of dialysis when neutrophil count was normal. (3) An inhibition of chemiluminescence of neutrophils isolated 5 and 15 min after the start of dialysis was noted. (4) Reuse of the membrane induced during the second use a significant aggravation of neutropenia (36 ± 23% at 15 min), a drop in platelet count (91 ± 10% at 15 min) and a return to normal of chemiluminescence. When compared to the results observed with cuprophane and polyacrilonitrile membranes in the same patients, the polycarbonate membrane seems to possess intermediate biocompatibility properties.

Keywords:
Hemodialysis membranes, Biocompatibility, Polycarbonate, Dialyzer reuse
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.